Global Energy Prize awarded to three scientists from China, USA and Russia
The Prize in the Conventional Energy category went to Jinliang He, chair of High Voltage Engineering Research Institute, professor at China's Tsinghua University. "This honour not only recognises my work alone, but also the collective endeavor of great minds advancing sustainable energy supply. It illuminates a shared vision to power world safely and efficiently. I dedicate this honour toward bridging innovation and advanced technologies for ultra-high voltage transmission systems," said Jinliang He.
For the first time in the history of the Prize, the award in the Non-Conventional Energy category was given to a woman, Yu Huang, professor and department head at the University of California, Los Angeles (USA). She will be awarded for innovations in the field of catalyst development, which significantly improve the profitability, durability and performance of fuel cells.
"I'm deeply honoured and truly humbled to receive this prestigious award. My group develops designer catalysts and we work to bridge the gap between discovery and deployment, turning new materials into working for energy conversion and storage. I have been fortunate enough to work with an extraordinary group of students, postdocs and collaborators. Their creativity and passion are making all of this possible," said Yu Huang.
Russian scientist Vladislav Khomich, head of research at the Institute for Electrophysics and Electric Power of the Russian Academy of Sciences (RAS), won in the New Ways of Energy Application category. He will receive the Prize for outstanding contributions to the development, creation and fundamental research of plasma technologies and pulsed energy.
The names of the laureates of the Prize were selected from a shortlist of 15 scientists from 8 countries. A total of 90 submissions from 44 countries and territories across the world were included in the nomination cycle.
The Committee, headed by the Nobel Peace Prize Laureate Rae Kwon Chung, made the final decision.
said Rae Kwon Chung.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
5 hours ago
- Cision Canada
Canada's new lunar utility rover will help astronauts build a future on the Moon Français
LONGUEUIL, QC, July 29, 2025 /CNW/ - Establishing a sustainable human presence on the Moon is an ambitious endeavour that requires international collaboration. A new generation of rovers with different capabilities will be essential, and partners around the world are working together to develop complementary technologies for the lunar surface. Today, the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, announced the award of three contracts totalling $14.6 million to advance the development of the new Canadian lunar utility rover. This investment marks the beginning of a long-term project that will draw on the skills and determination of experts across the country. Canada's utility rover is set to provide critical assistance to astronauts and support operations, including transporting cargo, performing logistics and construction duties on the Moon. Over the next 18 months, Canadensys Aerospace Corporation, MDA Space and Mission Control will conduct preparatory studies to assess different options for the rover, including potential capacities depending on different sizes and scope. The utility rover builds on decades of past investments in technology development that helped secure Canada's expertise in robotics, including rovers, and position our space sector for future opportunities related to lunar surface mobility. The Canadian Space Agency (CSA) aims to develop a utility rover that lives up to both Canada's rich legacy in space and future ambitions for space exploration. These investments bring us closer to having a CSA astronaut live and work on the surface of the Moon. Quotes "Our government is steadfast in its commitment to championing ambitious initiatives that spark innovation and elevate Canada's leadership on the global stage. Through the design and development of this lunar utility rover, Canada will collaborate with international partners to shape the next era of human exploration of the Moon. Ultimately, the advancement of the lunar utility rover has the potential to open doors for Canadian businesses to expand and compete internationally and is expected to create and maintain 200 well-paying jobs over the next decade in an industrial sector that is amongst the most innovative and R&D intensive." - The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions "Through smart and strategic procurement, our government is supporting cutting-edge technologies that not only honour our legacy in space but also pave the way for a Canadian astronaut to one day live and work on the Moon. Public Services and Procurement Canada is proud to play a key role in delivering the tools and partnerships that make this vision possible while supporting Canadian innovation and our economy." - The Honourable Joël Lightbound, Minister of Government Transformation, Public Works and Procurement Quick facts Associated links A Canadian utility rover on the Moon Moon exploration Rover fleet RSS Facebook YouTube X
Cision Canada
6 hours ago
- Cision Canada
CDA Issues Positive Reimbursement Recommendation for SKYCLARYS™ (omaveloxolone), the Only Health Canada-Approved Treatment for Managing Friedreich Ataxia Français
Final CDA recommendation reflects the urgent unmet need in a progressive, life-limiting condition and recognizes the value of a therapy that slows disease progression Regional differences in disease burden make focus on Quebec and Eastern Canada especially important TORONTO, July 29, 2025 /CNW/ - Biogen Canada Inc. is pleased to announce a significant step forward for Canadians living with Friedreich ataxia (FA), with the positive reimbursement recommendation by Canada's Drug Agency (CDA) Canadian Drug Expert Committee (CDEC) for SKYCLARYS™ (omaveloxolone) as a treatment for patients 16 years of age and older who meet certain criteria. 1 This milestone brings Canadians outside Quebec affected by this rare neurodegenerative disease a step closer to accessing the only approved therapy for the condition. The CDA recommendation is based on an assessment of clinical trial and economic evidence with input from physicians, patients and caregivers. The clinical evidence presented was from the Phase II MOXIe Part 2 trial, which showed that SKYCLARYS significantly slowed neurological decline compared to placebo as measured by the modified Friedreich Ataxia Rating Scale (mFARS), a tool used to assess neurological decline and disease progression. The individuals enrolled in the clinical trial were monitored over a 48-week period and showed reduced decline in their abilities when performing activities of daily living, which are essential for maintaining independence. 2 "For individuals affected by this progressive genetic disease, even a modest slowing in disease progression can have a profound impact on their lives," said Stacey Lintern, Chief Executive Officer, Muscular Dystrophy Canada. "Friedreich ataxia is a life-limiting condition that has been marked by a lack of treatment options and longstanding unmet needs in Canada. The CDA recommendation represents an important step toward changing that reality by making treatment more accessible and offering patients and families much-needed choice in managing their condition. Advancements like SKYCLARYS bring renewed hope to patients and their families." A progressive and life-shortening genetic disease, FA has a devastating impact on those diagnosed, reducing quality of life and limiting life expectancy to an average of 37 years. 3,4,5 In Canada, it is estimated to affect 1 in 40,000 individuals. 6 "We are encouraged by the CDA's recognition of SKYCLARYS as vital therapy for the Friedreich ataxia community, representing critical progress for this life-altering disease in urgent need of treatment options. In regions like Quebec and Eastern Canada, where more people are affected by FA, the need for timely access to new treatment options is especially urgent," said François-Olivier Théberge, General Manager of Ataxia Canada. "FA takes a heavy toll—people and families living with the disease face significant and often overwhelming challenges. For over 53 years, Ataxia Canada has been driven by the vision of our founder, Claude St-Jean, who believed deeply in the power of science and community to bring hope to those affected by rare diseases. We remain committed to his mission to advocate for equitable access in all provinces, including Quebec, and look forward to helping ensure that all Canadians living with Friedreich ataxia have a fair chance to benefit from SKYCLARYS." The CDA recommendation marks an important turning point in improving treatment options for individuals living with Friedreich ataxia. "This milestone represents much needed progress in addressing a longstanding unmet need for Canadians living with Friedreich ataxia," said Eric Tse, General Manager, Biogen Canada Inc. "Biogen is proud to be at the forefront of innovation in rare and serious neurodegenerative diseases, and remains committed to working collaboratively with healthcare systems and decision makers across Canada to support timely and equitable access to a treatment that will set the new standard of care in the management of FA." About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment, to deliver long-term growth. Biogen has been proudly serving Canadian patients for more than 25 years. For information about Biogen Canada, please visit
Globe and Mail
16 hours ago
- Globe and Mail
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's ' Cutaneous T-cell lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report In July 2025, Prescient Therapeutics Ltd. announced a phase 2 study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). In July 2025, Dren Bio conducted a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas. In July 2025, Soligenix announced a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. DelveInsight's Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment. The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others. Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment Cutaneous T-cell lymphoma Emerging Drugs HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States. AFM13: Affimed GmbH AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma. ASTX660: Otsuka Pharmaceutical Co., Ltd ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL. WUCART007: Wugen WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL. The Cutaneous T-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment. Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs Cutaneous T-Cell Lymphoma Companies HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Cutaneous T-Cell Lymphoma Pipeline Report Coverage- Global Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others. Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies Table of Content Introduction Executive Summary Cutaneous T-cell lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Cutaneous T-cell lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Mid Stage Products (Phase II) AFM13: Affimed GmbH Early Stage Products (Phase I) WUCART007: Wugen Preclinical Stage Products Drug Name: Company Name Inactive Products Cutaneous T-cell lymphoma Key Companies Cutaneous T-cell lymphoma Key Products Cutaneous T-cell lymphoma- Unmet Needs Cutaneous T-cell lymphoma- Market Drivers and Barriers Cutaneous T-cell lymphoma- Future Perspectives and Conclusion Cutaneous T-cell lymphoma Analyst Views Cutaneous T-cell lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
